Objective: To investigate the feasibility and safety of a robotic surgical system (or laparoscopy) in combination with colonoscopy (combined) for the treatment of stage T1N0M0 colorectal cancer. Methods: This was a descriptive case series. Indications for combined dual-scope surgery in this study were as follows: (1) preoperative colonoscopic examination of lesions in the middle and upper rectum and colon with pathologically confirmed high-grade intraepithelial neoplasia, intramucosal adenocarcinoma, or adenocarcinoma; (2) no distant or local lymph node metastases; and (3) endoscopic ultrasound and magnetic resonance imaging evidence of tumor invasion of the mucosal or submucosal, but not the muscular, layer (i.e., T1). The clinical data of 13 patients with stage T1 colorectal cancer who had undergone dual-scope combined resection using a robotic surgery system or laparoscope-assisted combined colonoscopy surgery at the First Affiliated Hospital of Zhengzhou University from April to October 2022 were retrospectively collected, including 6 males and 7 females, with a median age of 59 (48~88) years old. The tumors were located in the upper and middle rectum in six patients, in the sigmoid colon in three, and in the ascending colon in four. The median maximum diameter of the tumors was 3.0 (1.8-5.0) cm. The surgery was performed by a robotic surgery system (or laparoscopy) with peritumoral D1 lymph node dissection at the first station in the tumor area. The tumors were resected under direct vision and the defects in the intestinal wall were using a robotic surgery system (or laparoscopy). A robotic surgery system was combined with colonoscopy in eight cases and laparoscopy combined with colonoscopy in the remaining five. Studied variables includes surgical and pathological features, postoperative factors, and outcomes. Results: Surgery was successful in all 13 patients with no need for conversion to open surgery or intraoperative blood transfusion. The median operating time was 85 (60-120) minutes, median intraoperative bleeding 3 (2-5) mL, median number of lymph nodes harvested 3 (1-5), and the median circumferential resection margin 0.8 (0.5-1.0) cm. Postoperative pathological examination showed lymph node metastasis in one patient, who therefore underwent additional radical surgery. The median postoperative time to ambulation was 1 (1-2) days. The urinary catheters of all patients were removed 1 day after surgery and the median length of stay was 4 (3-5) days. No abdominal infection, anastomotic leakage or bleeding occurred in any of the study patients. The median follow-up time was 10 (6-12) months, during which no tumor recurrence or metastasis was found, and the quality of life was satisfactory. Conclusions: The combination of two minimally invasive platforms, a robotic surgery system (or laparoscopy) and colonoscopy, is safe and feasible for resection of stage T1 colorectal cancer and has a good short-term prognosis.
目的： 探讨机器人手术系统（或腹腔镜）联合结肠镜（双镜联合）治疗T1期（T1N0M0）结直肠癌的可行性及安全性。 方法： 采用描述性病例系列研究的方法。本研究中双镜联合手术适应证：（1）术前经肠镜检查病变部位为直肠中上段以及结肠，病理证实为高级别上皮内瘤变、黏膜内腺癌或腺癌；（2）无远处转移以及局部淋巴结转移；（3）内镜超声及MRI提示肿瘤侵犯深度为黏膜或黏膜下层即T1，未侵及肌层。回顾性收集2022年4—10月期间，在郑州大学第一附属医院应用机器人手术系统或腹腔镜辅助联合结肠镜行双镜联合切除术治疗的13例T1期结直肠癌患者的临床资料。其中男性6例，女性7例，中位年龄59（48~88）岁；肿瘤位于直肠中上段6例，乙状结肠3例，升结肠4例；肿瘤最大径中位数3.0（1.8~5.0）cm；手术方法为机器人手术系统（或腹腔镜）下行肿瘤区域肠壁裸化及第一站淋巴结清扫；结肠镜肠腔内直视下全层切除肿瘤；利用机器人手术系统（或腹腔镜）协助肿瘤切除并修复肠壁缺损。机器人手术系统联合结肠镜手术8例，腹腔镜联合结肠镜手术5例。观察手术情况、围手术期情况和术后病理以及随访情况。 结果： 13例患者手术均顺利完成，无中转开腹或术中输血。中位手术时间85（60~120）min，中位术中出血量3（2~5）ml，淋巴结清扫中位数3（1~5）枚，肿瘤环周切缘中位距离0.8（0.5~1.0）cm；其中1例术后病理示淋巴结转移，予以追加根治性手术。全组患者术后中位排气时间1（1~2）d，均在术后1 d拔除尿管并下床活动，中位住院时间4（3~5）d。全组均未出现腹腔感染、吻合口漏及出血。全组患者中位随访时间10（6~12）个月，均未发现肿瘤复发及转移，生活质量满意。 结论： 机器人手术系统（或腹腔镜）与结肠镜两种微创平台优势互补，联合进行T1期结直肠癌切除手术安全可行，且术后短期预后良好。.